Diabetes & vascular disease research · 2016
Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arnetz Lisa, Hage Camilla, Brismar Kerstin, Catrina Sergiu-Bogdan, Norhammar Anna, Lundman Pia, Wallander Märit, Ryden Lars, Mellbin Linda
Аннотация
PURPOSE: To investigate whether sitagliptin affects copeptin and osmolality, suggesting arginine vasopressin activation and a potential for fluid retention, compared with placebo, in patients with a recent acute coronary syndrome and newly discovered type 2 diabetes or impaired glucose tolerance. A second aim was to confirm whether copeptin correlated with insulin-like growth factor binding protein-1.
METHODS: Fasting blood samples were used from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction trial, in which patients recently hospitalized due to acute coronary syndrome and with newly detected abnormal glucose tolerance were randomized to sitagliptin 100 mg once daily (n = 34) or placebo (n = 37). Copeptin, osmolality and insulin-like growth factor binding protein-1 were analysed at baseline and after 12 weeks.
RESULTS: Copeptin and osmolality were unaffected by sitagliptin. There was no correlation between copeptin and insulin-like growth factor binding protein-1.
CONCLUSION: Sitagliptin therapy does not appear to be related to activation of the arginine vasopressin system.
METHODS: Fasting blood samples were used from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction trial, in which patients recently hospitalized due to acute coronary syndrome and with newly detected abnormal glucose tolerance were randomized to sitagliptin 100 mg once daily (n = 34) or placebo (n = 37). Copeptin, osmolality and insulin-like growth factor binding protein-1 were analysed at baseline and after 12 weeks.
RESULTS: Copeptin and osmolality were unaffected by sitagliptin. There was no correlation between copeptin and insulin-like growth factor binding protein-1.
CONCLUSION: Sitagliptin therapy does not appear to be related to activation of the arginine vasopressin system.
Предметные рубрики MeSH
Acute Coronary SyndromeAgedAged, 80 and overBiomarkersDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodDrug Administration ScheduleFemaleGlycopeptidesHospitalizationHumansInsulin-Like Growth Factor Binding Protein 1Insulin-Secreting CellsMaleMiddle AgedMyocardial InfarctionNeurophysinsOsmolar ConcentrationProtein PrecursorsSitagliptin PhosphateSwedenTime FactorsTreatment OutcomeVasopressinsWater-Electrolyte Balance